Merck Announces Fourth-Quarter and Full-Year 2023 Financial …
Merck Announces Fourth-Quarter and Full-Year 2023 Financial … Obtained FDA Priority Review of Biologics License Applications for V116, an Investigational Pneumococcal Conjugate Vaccine, as Well as Merck and Daiichi Sankyo’s Patritumab … Obtained FDA Priority Review of Biologics License Applications for V116, an Investigational Pneumococcal Conjugate Vaccine, as Well as Merck and Daiichi Sankyo’s Patritumab …
Related contacts of this company（?）
All丨 CEO/Owner/Chairman丨 President/VP/General丨 Purchas/Buy/Import丨 Direct/Manage丨 Engineer/Design
Serial number name Job Title Job Email Operate
View contacts One-click detection Export result One-click marketing